Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Multiple myeloma (MM) is a heterogeneous and ultimately fatal disease. Risk stratification using prognostic biomarkers is crucial to individualize treatments. We sought to investigate the role of CD99, a transmembrane protein highly expressed in many hematopoietic cells including subpopulations of normal and neoplastic plasma cells, for MM risk stratification. Methods: CD99 expression was measured in paraffin samples of bone marrow and extramedullary biopsies of 170 patients with MM. Patients were divided into those with high score (moderately andstrongly positive) and low score (negative and weakly positive), with all staining being cytoplasmic and/or membranous. Results: High anti-CD99 immunostaining was observed in 72 of 136 (52.9%) bone marrow biopsies and 24 of 87 (27.6%) extramedullary biopsies in MM. High CD99 expression of extramedullary specimens was associated with significantly longer overall survival (OS; p=.016). High CD99 expression of extramedullary specimens was also associated with better prognosis in the nonautologous stem cell transplantation group of MM patients (p=.044). In multivariate analysis, International Staging System stage was an independent prognostic factor, whereas CD99 expression was no longer statistically significant. Conclusions: Expression of CD99 in extramedullary specimens was correlated with longer OS, suggesting that CD99 may be a helpful immunohistochemical marker for risk stratification.
Abstract
Background: Multiple myeloma (MM) is a heterogeneous and ultimately fatal disease. Risk stratification using prognostic biomarkers is crucial to individualize treatments. We sought to investigate the role of CD99, a transmembrane protein highly expressed in many hematopoietic cells including subpopulations of normal and neoplastic plasma cells, for MM risk stratification. Methods: CD99 expression was measured in paraffin samples of bone marrow and extramedullary biopsies of 170 patients with MM. Patients were divided into those with high score (moderately andstrongly positive) and low score (negative and weakly positive), with all staining being cytoplasmic and/or membranous. Results: High anti-CD99 immunostaining was observed in 72 of 136 (52.9%) bone marrow biopsies and 24 of 87 (27.6%) extramedullary biopsies in MM. High CD99 expression of extramedullary specimens was associated with significantly longer overall survival (OS; p=.016). High CD99 expression of extramedullary specimens was also associated with better prognosis in the nonautologous stem cell transplantation group of MM patients (p=.044). In multivariate analysis, International Staging System stage was an independent prognostic factor, whereas CD99 expression was no longer statistically significant. Conclusions: Expression of CD99 in extramedullary specimens was correlated with longer OS, suggesting that CD99 may be a helpful immunohistochemical marker for risk stratification.
참고문헌 (30)
- Jemal A, "Cancer statistics, 2007", CA Cancer J Clin, 57, pp.43~66 (2007)
- Kumar L, "Recent advances in the management of multiple myeloma", Natl Med J India, 23, pp.210~218 (2010)
- Cavo M, "The changing landscape of myeloma therapy", N Engl J Med, 354, pp.1076~1078 (2006)
- Kumar SK, "Improved survival in multiple myeloma and the impact of novel therapies", Blood, 111, pp.2516~2520 (2008)
- Bergsagel PL, "Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma", Blood, 106, pp.296~303 (2005)
- Zhan F, "The molecular classification of multiple myeloma", Blood, 108, pp.2020~2028 (2006)
- Barlogie B, "Williams hematology", pp.1279~1304 (2001), McGraw-Hill
- Inamoto Y, "Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation", Am J Hematol, 84, pp.283~286 (2009)
- Kleber M, "Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal", Clin Lymphoma Myeloma Leuk, 12, pp.38~48 (2012)
- Gutiérrez NC, "Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis", Leukemia, 21, pp.143~150 (2007)
- Rajkumar S, "Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma", Bone Marrow Transplant, 24, pp.497~503 (1999)
- Fonseca R, "Clinical and biologic implications of recurrent genomic aberrations in myeloma", Blood, 101, pp.4569~4575 (2003)
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.202~ (2008), IARC Press
- Stewart AK, "A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy", Leukemia, 21, pp.529~534 (2007)
- Hamilton G, "Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen", Cancer Res, 48, pp.6127~6131 (1988)
- Pan Y, "A clinicopathological study of 96 cases of lymphoblastic lymphoma", Zhonghua Xue Ye Xue Za Zhi, 26, pp.218~222 (2005)
- Riopel M, "MIC2 analysis in pediatric lymphomas and leukemias", Hum Pathol, 25, pp.396~399 (1994)
- Zhang PJ, "Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases", Mod Pathol, 13, pp.452~458 (2000)
- Buxton D, "Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases", Am J Clin Pathol, 131, pp.574~579 (2009)
- 성창옥, "Immunoreactivity of CD99 in Non-Hodgkin ’s Lymphoma :Unexpected Frequent Expression in ALK-positive Anaplastic Large Cell Lymphoma", Journal of Korean Medical Science, 20(6), pp.952~956 (2005), 대한의학회
- Lee SP, "Clinicopathologic Characteristics of CD99-Positive Diffuse Large B-Cell Lymphoma", ACTA HAEMATOLOGICA, 125(3), pp.167~174 (2011), KARGER
- Park CK, "High CD99 expression in memory T and B cells in reactive lymph nodes", J Korean Med Sci, 14, pp.600~606 (1999)
- Xuan Y, "Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder", J Cancer Res Clin Oncol, 137, pp.49~54 (2011)
- Goto A, "Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs)", Histopathology, 45, pp.384~392 (2004)
- Pelosi G, "CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours", Virchows Arch, 437, pp.270~274 (2000)
- 홍준식, "CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy", ANNALS OF HEMATOLOGY, 91(12), pp.1897~1906 (2012), SPRINGER
- Scotlandi K, "CD99 engagement: an effective therapeutic strategy for Ewing tumors", Cancer Res, 60, pp.5134~5142 (2000)
- Kreppel M, "Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells", Oncogene, 25, pp.2795~2800 (2006)
- Kim MK, "MHC class II engagement inhibits CD99-induced apoptosis and up-regulation of T cell receptor and MHC molecules in human thymocytes and T cell line", FEBS Lett, 546, pp.379~384 (2003)
- Imbert AM, "CD99 expressed on human mobilized peripheral blood CD34+ cells is involved in transendothelial migration", Blood, 108, pp.2578~2586 (2006)